nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—CYP1A1—Dacarbazine—pancreatic cancer	0.112	0.17	CbGbCtD
Dexmedetomidine—CYP1A1—Tamoxifen—pancreatic cancer	0.0887	0.135	CbGbCtD
Dexmedetomidine—CYP2E1—Dacarbazine—pancreatic cancer	0.0861	0.131	CbGbCtD
Dexmedetomidine—CYP1A1—Erlotinib—pancreatic cancer	0.0754	0.115	CbGbCtD
Dexmedetomidine—CYP2E1—Tamoxifen—pancreatic cancer	0.0685	0.104	CbGbCtD
Dexmedetomidine—CYP1A2—Dacarbazine—pancreatic cancer	0.0498	0.0758	CbGbCtD
Dexmedetomidine—CYP1A2—Tamoxifen—pancreatic cancer	0.0396	0.0603	CbGbCtD
Dexmedetomidine—CYP1A2—Erlotinib—pancreatic cancer	0.0337	0.0513	CbGbCtD
Dexmedetomidine—CYP2D6—Tamoxifen—pancreatic cancer	0.0327	0.0497	CbGbCtD
Dexmedetomidine—CYP1A2—Fluorouracil—pancreatic cancer	0.0292	0.0445	CbGbCtD
Dexmedetomidine—CYP2D6—Erlotinib—pancreatic cancer	0.0278	0.0423	CbGbCtD
Dexmedetomidine—CYP2D6—Doxorubicin—pancreatic cancer	0.0137	0.0209	CbGbCtD
Dexmedetomidine—Hyperkalaemia—Doxorubicin—pancreatic cancer	0.000388	0.00151	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Epirubicin—pancreatic cancer	0.00038	0.00147	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.000379	0.00147	CcSEcCtD
Dexmedetomidine—Fluid retention—Doxorubicin—pancreatic cancer	0.000375	0.00145	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.000375	0.00145	CcSEcCtD
Dexmedetomidine—Blood urea increased—Doxorubicin—pancreatic cancer	0.000373	0.00145	CcSEcCtD
Dexmedetomidine—Abnormal vision—Epirubicin—pancreatic cancer	0.000372	0.00144	CcSEcCtD
Dexmedetomidine—Sepsis—Epirubicin—pancreatic cancer	0.00037	0.00144	CcSEcCtD
Dexmedetomidine—Anaemia—Irinotecan—pancreatic cancer	0.00037	0.00143	CcSEcCtD
Dexmedetomidine—Abdominal pain—Tamoxifen—pancreatic cancer	0.000366	0.00142	CcSEcCtD
Dexmedetomidine—Body temperature increased—Erlotinib—pancreatic cancer	0.000362	0.0014	CcSEcCtD
Dexmedetomidine—Abdominal pain—Erlotinib—pancreatic cancer	0.000362	0.0014	CcSEcCtD
Dexmedetomidine—Anaemia—Gemcitabine—pancreatic cancer	0.00036	0.0014	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Epirubicin—pancreatic cancer	0.000356	0.00138	CcSEcCtD
Dexmedetomidine—Pneumonia—Docetaxel—pancreatic cancer	0.000356	0.00138	CcSEcCtD
Dexmedetomidine—Hepatic function abnormal—Epirubicin—pancreatic cancer	0.000355	0.00138	CcSEcCtD
Dexmedetomidine—Anaemia—Fluorouracil—pancreatic cancer	0.000354	0.00137	CcSEcCtD
Dexmedetomidine—Dyspnoea—Sunitinib—pancreatic cancer	0.000354	0.00137	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Doxorubicin—pancreatic cancer	0.000352	0.00136	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Docetaxel—pancreatic cancer	0.000349	0.00135	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Docetaxel—pancreatic cancer	0.000347	0.00135	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Docetaxel—pancreatic cancer	0.000347	0.00135	CcSEcCtD
Dexmedetomidine—Hypertension—Irinotecan—pancreatic cancer	0.000346	0.00134	CcSEcCtD
Dexmedetomidine—Abnormal vision—Doxorubicin—pancreatic cancer	0.000344	0.00134	CcSEcCtD
Dexmedetomidine—Sepsis—Doxorubicin—pancreatic cancer	0.000343	0.00133	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000342	0.00133	CcSEcCtD
Dexmedetomidine—Pain—Sunitinib—pancreatic cancer	0.000339	0.00132	CcSEcCtD
Dexmedetomidine—Constipation—Sunitinib—pancreatic cancer	0.000339	0.00132	CcSEcCtD
Dexmedetomidine—Hypertension—Gemcitabine—pancreatic cancer	0.000337	0.00131	CcSEcCtD
Dexmedetomidine—Renal failure acute—Epirubicin—pancreatic cancer	0.000336	0.0013	CcSEcCtD
Dexmedetomidine—Convulsion—Fluorouracil—pancreatic cancer	0.000332	0.00129	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Doxorubicin—pancreatic cancer	0.00033	0.00128	CcSEcCtD
Dexmedetomidine—Confusional state—Irinotecan—pancreatic cancer	0.000329	0.00128	CcSEcCtD
Dexmedetomidine—Hepatic function abnormal—Doxorubicin—pancreatic cancer	0.000328	0.00127	CcSEcCtD
Dexmedetomidine—Infection—Irinotecan—pancreatic cancer	0.000325	0.00126	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000324	0.00126	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Irinotecan—pancreatic cancer	0.00032	0.00124	CcSEcCtD
Dexmedetomidine—Haemoglobin—Docetaxel—pancreatic cancer	0.000319	0.00124	CcSEcCtD
Dexmedetomidine—Haemorrhage—Docetaxel—pancreatic cancer	0.000318	0.00123	CcSEcCtD
Dexmedetomidine—Hypoglycaemia—Epirubicin—pancreatic cancer	0.000318	0.00123	CcSEcCtD
Dexmedetomidine—Diarrhoea—Tamoxifen—pancreatic cancer	0.000317	0.00123	CcSEcCtD
Dexmedetomidine—Infection—Gemcitabine—pancreatic cancer	0.000316	0.00123	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Irinotecan—pancreatic cancer	0.000316	0.00122	CcSEcCtD
Dexmedetomidine—Confusional state—Fluorouracil—pancreatic cancer	0.000315	0.00122	CcSEcCtD
Dexmedetomidine—Abdominal pain—Sunitinib—pancreatic cancer	0.000313	0.00122	CcSEcCtD
Dexmedetomidine—Body temperature increased—Sunitinib—pancreatic cancer	0.000313	0.00122	CcSEcCtD
Dexmedetomidine—Diarrhoea—Erlotinib—pancreatic cancer	0.000313	0.00122	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Docetaxel—pancreatic cancer	0.000313	0.00121	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.000312	0.00121	CcSEcCtD
Dexmedetomidine—Infection—Fluorouracil—pancreatic cancer	0.000311	0.00121	CcSEcCtD
Dexmedetomidine—Renal failure acute—Doxorubicin—pancreatic cancer	0.000311	0.0012	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.000308	0.00119	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.000306	0.00119	CcSEcCtD
Dexmedetomidine—Visual impairment—Docetaxel—pancreatic cancer	0.000306	0.00119	CcSEcCtD
Dexmedetomidine—Dizziness—Tamoxifen—pancreatic cancer	0.000306	0.00119	CcSEcCtD
Dexmedetomidine—Tachycardia—Fluorouracil—pancreatic cancer	0.000305	0.00118	CcSEcCtD
Dexmedetomidine—Hypotension—Irinotecan—pancreatic cancer	0.000305	0.00118	CcSEcCtD
Dexmedetomidine—Dizziness—Erlotinib—pancreatic cancer	0.000303	0.00118	CcSEcCtD
Dexmedetomidine—Hypotension—Gemcitabine—pancreatic cancer	0.000297	0.00115	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Docetaxel—pancreatic cancer	0.000295	0.00114	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Epirubicin—pancreatic cancer	0.000295	0.00114	CcSEcCtD
Dexmedetomidine—Vomiting—Tamoxifen—pancreatic cancer	0.000294	0.00114	CcSEcCtD
Dexmedetomidine—Hypoglycaemia—Doxorubicin—pancreatic cancer	0.000294	0.00114	CcSEcCtD
Dexmedetomidine—Hypotension—Fluorouracil—pancreatic cancer	0.000292	0.00113	CcSEcCtD
Dexmedetomidine—Rash—Tamoxifen—pancreatic cancer	0.000292	0.00113	CcSEcCtD
Dexmedetomidine—Dermatitis—Tamoxifen—pancreatic cancer	0.000292	0.00113	CcSEcCtD
Dexmedetomidine—Vomiting—Erlotinib—pancreatic cancer	0.000291	0.00113	CcSEcCtD
Dexmedetomidine—Dyspnoea—Irinotecan—pancreatic cancer	0.000291	0.00113	CcSEcCtD
Dexmedetomidine—Somnolence—Irinotecan—pancreatic cancer	0.00029	0.00113	CcSEcCtD
Dexmedetomidine—Headache—Tamoxifen—pancreatic cancer	0.00029	0.00113	CcSEcCtD
Dexmedetomidine—Rash—Erlotinib—pancreatic cancer	0.000289	0.00112	CcSEcCtD
Dexmedetomidine—Dermatitis—Erlotinib—pancreatic cancer	0.000289	0.00112	CcSEcCtD
Dexmedetomidine—Angiopathy—Docetaxel—pancreatic cancer	0.000288	0.00112	CcSEcCtD
Dexmedetomidine—Headache—Erlotinib—pancreatic cancer	0.000287	0.00111	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Docetaxel—pancreatic cancer	0.000286	0.00111	CcSEcCtD
Dexmedetomidine—Chills—Docetaxel—pancreatic cancer	0.000285	0.00111	CcSEcCtD
Dexmedetomidine—Arrhythmia—Docetaxel—pancreatic cancer	0.000284	0.0011	CcSEcCtD
Dexmedetomidine—Dyspnoea—Gemcitabine—pancreatic cancer	0.000284	0.0011	CcSEcCtD
Dexmedetomidine—Somnolence—Gemcitabine—pancreatic cancer	0.000283	0.0011	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Epirubicin—pancreatic cancer	0.000282	0.00109	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000282	0.00109	CcSEcCtD
Dexmedetomidine—Constipation—Irinotecan—pancreatic cancer	0.000279	0.00108	CcSEcCtD
Dexmedetomidine—Pain—Irinotecan—pancreatic cancer	0.000279	0.00108	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	0.000279	0.00108	CcSEcCtD
Dexmedetomidine—Dyspnoea—Fluorouracil—pancreatic cancer	0.000279	0.00108	CcSEcCtD
Dexmedetomidine—Mental disorder—Docetaxel—pancreatic cancer	0.000278	0.00108	CcSEcCtD
Dexmedetomidine—Somnolence—Fluorouracil—pancreatic cancer	0.000278	0.00108	CcSEcCtD
Dexmedetomidine—Malnutrition—Docetaxel—pancreatic cancer	0.000277	0.00107	CcSEcCtD
Dexmedetomidine—Nausea—Tamoxifen—pancreatic cancer	0.000275	0.00107	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000275	0.00107	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	0.000273	0.00106	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Doxorubicin—pancreatic cancer	0.000273	0.00106	CcSEcCtD
Dexmedetomidine—Pain—Gemcitabine—pancreatic cancer	0.000272	0.00106	CcSEcCtD
Dexmedetomidine—Constipation—Gemcitabine—pancreatic cancer	0.000272	0.00106	CcSEcCtD
Dexmedetomidine—Nausea—Erlotinib—pancreatic cancer	0.000272	0.00106	CcSEcCtD
Dexmedetomidine—Diarrhoea—Sunitinib—pancreatic cancer	0.000271	0.00105	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00027	0.00105	CcSEcCtD
Dexmedetomidine—Abdominal distension—Epirubicin—pancreatic cancer	0.00027	0.00105	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Irinotecan—pancreatic cancer	0.000269	0.00104	CcSEcCtD
Dexmedetomidine—Pain—Fluorouracil—pancreatic cancer	0.000268	0.00104	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000267	0.00104	CcSEcCtD
Dexmedetomidine—Dizziness—Sunitinib—pancreatic cancer	0.000262	0.00102	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000262	0.00102	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Doxorubicin—pancreatic cancer	0.000261	0.00101	CcSEcCtD
Dexmedetomidine—Abdominal pain—Irinotecan—pancreatic cancer	0.000258	0.001	CcSEcCtD
Dexmedetomidine—Body temperature increased—Irinotecan—pancreatic cancer	0.000258	0.001	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.000258	0.001	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000258	0.001	CcSEcCtD
Dexmedetomidine—Anaemia—Docetaxel—pancreatic cancer	0.000256	0.000992	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.000253	0.000981	CcSEcCtD
Dexmedetomidine—Vomiting—Sunitinib—pancreatic cancer	0.000252	0.000978	CcSEcCtD
Dexmedetomidine—Body temperature increased—Gemcitabine—pancreatic cancer	0.000252	0.000976	CcSEcCtD
Dexmedetomidine—Rash—Sunitinib—pancreatic cancer	0.00025	0.00097	CcSEcCtD
Dexmedetomidine—Dermatitis—Sunitinib—pancreatic cancer	0.00025	0.000969	CcSEcCtD
Dexmedetomidine—Abdominal distension—Doxorubicin—pancreatic cancer	0.000249	0.000968	CcSEcCtD
Dexmedetomidine—Headache—Sunitinib—pancreatic cancer	0.000248	0.000964	CcSEcCtD
Dexmedetomidine—Body temperature increased—Fluorouracil—pancreatic cancer	0.000247	0.000959	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000242	0.000937	CcSEcCtD
Dexmedetomidine—Pneumonia—Epirubicin—pancreatic cancer	0.00024	0.000932	CcSEcCtD
Dexmedetomidine—Convulsion—Docetaxel—pancreatic cancer	0.00024	0.00093	CcSEcCtD
Dexmedetomidine—Hypertension—Docetaxel—pancreatic cancer	0.000239	0.000927	CcSEcCtD
Dexmedetomidine—Nausea—Sunitinib—pancreatic cancer	0.000236	0.000914	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Epirubicin—pancreatic cancer	0.000234	0.000908	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Epirubicin—pancreatic cancer	0.000232	0.0009	CcSEcCtD
Dexmedetomidine—Dry mouth—Docetaxel—pancreatic cancer	0.00023	0.000894	CcSEcCtD
Dexmedetomidine—Confusional state—Docetaxel—pancreatic cancer	0.000228	0.000883	CcSEcCtD
Dexmedetomidine—Infection—Docetaxel—pancreatic cancer	0.000224	0.00087	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000224	0.000867	CcSEcCtD
Dexmedetomidine—Diarrhoea—Irinotecan—pancreatic cancer	0.000224	0.000867	CcSEcCtD
Dexmedetomidine—Pneumonia—Doxorubicin—pancreatic cancer	0.000222	0.000862	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000221	0.000858	CcSEcCtD
Dexmedetomidine—Tachycardia—Docetaxel—pancreatic cancer	0.00022	0.000855	CcSEcCtD
Dexmedetomidine—Bradycardia—Epirubicin—pancreatic cancer	0.000218	0.000847	CcSEcCtD
Dexmedetomidine—Diarrhoea—Gemcitabine—pancreatic cancer	0.000218	0.000845	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Doxorubicin—pancreatic cancer	0.000217	0.00084	CcSEcCtD
Dexmedetomidine—Dizziness—Irinotecan—pancreatic cancer	0.000216	0.000838	CcSEcCtD
Dexmedetomidine—Haemoglobin—Epirubicin—pancreatic cancer	0.000215	0.000836	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000215	0.000833	CcSEcCtD
Dexmedetomidine—Haemorrhage—Epirubicin—pancreatic cancer	0.000214	0.000832	CcSEcCtD
Dexmedetomidine—Diarrhoea—Fluorouracil—pancreatic cancer	0.000214	0.00083	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Epirubicin—pancreatic cancer	0.000211	0.000819	CcSEcCtD
Dexmedetomidine—Hypotension—Docetaxel—pancreatic cancer	0.000211	0.000818	CcSEcCtD
Dexmedetomidine—Vomiting—Irinotecan—pancreatic cancer	0.000208	0.000806	CcSEcCtD
Dexmedetomidine—Dizziness—Fluorouracil—pancreatic cancer	0.000207	0.000803	CcSEcCtD
Dexmedetomidine—Visual impairment—Epirubicin—pancreatic cancer	0.000207	0.000801	CcSEcCtD
Dexmedetomidine—Rash—Irinotecan—pancreatic cancer	0.000206	0.000799	CcSEcCtD
Dexmedetomidine—Dermatitis—Irinotecan—pancreatic cancer	0.000206	0.000798	CcSEcCtD
Dexmedetomidine—Headache—Irinotecan—pancreatic cancer	0.000205	0.000794	CcSEcCtD
Dexmedetomidine—Vomiting—Gemcitabine—pancreatic cancer	0.000202	0.000785	CcSEcCtD
Dexmedetomidine—Bradycardia—Doxorubicin—pancreatic cancer	0.000202	0.000783	CcSEcCtD
Dexmedetomidine—Dyspnoea—Docetaxel—pancreatic cancer	0.000201	0.000781	CcSEcCtD
Dexmedetomidine—Somnolence—Docetaxel—pancreatic cancer	0.000201	0.000779	CcSEcCtD
Dexmedetomidine—Rash—Gemcitabine—pancreatic cancer	0.000201	0.000778	CcSEcCtD
Dexmedetomidine—Dermatitis—Gemcitabine—pancreatic cancer	0.0002	0.000778	CcSEcCtD
Dexmedetomidine—Haemoglobin—Doxorubicin—pancreatic cancer	0.000199	0.000773	CcSEcCtD
Dexmedetomidine—Headache—Gemcitabine—pancreatic cancer	0.000199	0.000773	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Epirubicin—pancreatic cancer	0.000199	0.000772	CcSEcCtD
Dexmedetomidine—Vomiting—Fluorouracil—pancreatic cancer	0.000199	0.000772	CcSEcCtD
Dexmedetomidine—Haemorrhage—Doxorubicin—pancreatic cancer	0.000198	0.000769	CcSEcCtD
Dexmedetomidine—Rash—Fluorouracil—pancreatic cancer	0.000197	0.000765	CcSEcCtD
Dexmedetomidine—Dermatitis—Fluorouracil—pancreatic cancer	0.000197	0.000764	CcSEcCtD
Dexmedetomidine—Headache—Fluorouracil—pancreatic cancer	0.000196	0.00076	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000195	0.000758	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000195	0.000756	CcSEcCtD
Dexmedetomidine—Angiopathy—Epirubicin—pancreatic cancer	0.000195	0.000754	CcSEcCtD
Dexmedetomidine—Nausea—Irinotecan—pancreatic cancer	0.000194	0.000753	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000193	0.000749	CcSEcCtD
Dexmedetomidine—Pain—Docetaxel—pancreatic cancer	0.000193	0.000749	CcSEcCtD
Dexmedetomidine—Constipation—Docetaxel—pancreatic cancer	0.000193	0.000749	CcSEcCtD
Dexmedetomidine—Chills—Epirubicin—pancreatic cancer	0.000192	0.000746	CcSEcCtD
Dexmedetomidine—Arrhythmia—Epirubicin—pancreatic cancer	0.000192	0.000743	CcSEcCtD
Dexmedetomidine—Visual impairment—Doxorubicin—pancreatic cancer	0.000191	0.000741	CcSEcCtD
Dexmedetomidine—Nausea—Gemcitabine—pancreatic cancer	0.000189	0.000733	CcSEcCtD
Dexmedetomidine—Mental disorder—Epirubicin—pancreatic cancer	0.000188	0.000729	CcSEcCtD
Dexmedetomidine—Malnutrition—Epirubicin—pancreatic cancer	0.000187	0.000724	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Docetaxel—pancreatic cancer	0.000186	0.000722	CcSEcCtD
Dexmedetomidine—Nausea—Fluorouracil—pancreatic cancer	0.000186	0.000721	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000185	0.000716	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000184	0.000714	CcSEcCtD
Dexmedetomidine—Angiopathy—Doxorubicin—pancreatic cancer	0.00018	0.000698	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000179	0.000693	CcSEcCtD
Dexmedetomidine—Abdominal pain—Docetaxel—pancreatic cancer	0.000179	0.000692	CcSEcCtD
Dexmedetomidine—Body temperature increased—Docetaxel—pancreatic cancer	0.000179	0.000692	CcSEcCtD
Dexmedetomidine—Chills—Doxorubicin—pancreatic cancer	0.000178	0.00069	CcSEcCtD
Dexmedetomidine—Arrhythmia—Doxorubicin—pancreatic cancer	0.000177	0.000687	CcSEcCtD
Dexmedetomidine—Mental disorder—Doxorubicin—pancreatic cancer	0.000174	0.000674	CcSEcCtD
Dexmedetomidine—Malnutrition—Doxorubicin—pancreatic cancer	0.000173	0.00067	CcSEcCtD
Dexmedetomidine—Anaemia—Epirubicin—pancreatic cancer	0.000172	0.000669	CcSEcCtD
Dexmedetomidine—Agitation—Epirubicin—pancreatic cancer	0.000171	0.000665	CcSEcCtD
Dexmedetomidine—Convulsion—Epirubicin—pancreatic cancer	0.000162	0.000627	CcSEcCtD
Dexmedetomidine—Hypertension—Epirubicin—pancreatic cancer	0.000161	0.000625	CcSEcCtD
Dexmedetomidine—Anaemia—Doxorubicin—pancreatic cancer	0.00016	0.000619	CcSEcCtD
Dexmedetomidine—Agitation—Doxorubicin—pancreatic cancer	0.000159	0.000616	CcSEcCtD
Dexmedetomidine—Anxiety—Epirubicin—pancreatic cancer	0.000158	0.000614	CcSEcCtD
Dexmedetomidine—Dry mouth—Epirubicin—pancreatic cancer	0.000155	0.000603	CcSEcCtD
Dexmedetomidine—Diarrhoea—Docetaxel—pancreatic cancer	0.000155	0.000599	CcSEcCtD
Dexmedetomidine—Confusional state—Epirubicin—pancreatic cancer	0.000154	0.000596	CcSEcCtD
Dexmedetomidine—Infection—Epirubicin—pancreatic cancer	0.000151	0.000587	CcSEcCtD
Dexmedetomidine—Convulsion—Doxorubicin—pancreatic cancer	0.00015	0.00058	CcSEcCtD
Dexmedetomidine—Dizziness—Docetaxel—pancreatic cancer	0.000149	0.000579	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000149	0.000578	CcSEcCtD
Dexmedetomidine—Hypertension—Doxorubicin—pancreatic cancer	0.000149	0.000578	CcSEcCtD
Dexmedetomidine—Tachycardia—Epirubicin—pancreatic cancer	0.000149	0.000577	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000147	0.000571	CcSEcCtD
Dexmedetomidine—Anxiety—Doxorubicin—pancreatic cancer	0.000147	0.000568	CcSEcCtD
Dexmedetomidine—Dry mouth—Doxorubicin—pancreatic cancer	0.000144	0.000558	CcSEcCtD
Dexmedetomidine—Vomiting—Docetaxel—pancreatic cancer	0.000144	0.000557	CcSEcCtD
Dexmedetomidine—Rash—Docetaxel—pancreatic cancer	0.000142	0.000552	CcSEcCtD
Dexmedetomidine—Hypotension—Epirubicin—pancreatic cancer	0.000142	0.000552	CcSEcCtD
Dexmedetomidine—Dermatitis—Docetaxel—pancreatic cancer	0.000142	0.000552	CcSEcCtD
Dexmedetomidine—Confusional state—Doxorubicin—pancreatic cancer	0.000142	0.000551	CcSEcCtD
Dexmedetomidine—Headache—Docetaxel—pancreatic cancer	0.000141	0.000549	CcSEcCtD
Dexmedetomidine—Infection—Doxorubicin—pancreatic cancer	0.00014	0.000543	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000138	0.000535	CcSEcCtD
Dexmedetomidine—Tachycardia—Doxorubicin—pancreatic cancer	0.000138	0.000534	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000136	0.000528	CcSEcCtD
Dexmedetomidine—Dyspnoea—Epirubicin—pancreatic cancer	0.000136	0.000527	CcSEcCtD
Dexmedetomidine—Somnolence—Epirubicin—pancreatic cancer	0.000135	0.000525	CcSEcCtD
Dexmedetomidine—Nausea—Docetaxel—pancreatic cancer	0.000134	0.00052	CcSEcCtD
Dexmedetomidine—Hypotension—Doxorubicin—pancreatic cancer	0.000132	0.000511	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000131	0.00051	CcSEcCtD
Dexmedetomidine—Pain—Epirubicin—pancreatic cancer	0.00013	0.000505	CcSEcCtD
Dexmedetomidine—Constipation—Epirubicin—pancreatic cancer	0.00013	0.000505	CcSEcCtD
Dexmedetomidine—Dyspnoea—Doxorubicin—pancreatic cancer	0.000126	0.000487	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Epirubicin—pancreatic cancer	0.000126	0.000487	CcSEcCtD
Dexmedetomidine—Somnolence—Doxorubicin—pancreatic cancer	0.000125	0.000486	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000125	0.000483	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000122	0.000472	CcSEcCtD
Dexmedetomidine—Constipation—Doxorubicin—pancreatic cancer	0.000121	0.000467	CcSEcCtD
Dexmedetomidine—Pain—Doxorubicin—pancreatic cancer	0.000121	0.000467	CcSEcCtD
Dexmedetomidine—Abdominal pain—Epirubicin—pancreatic cancer	0.00012	0.000467	CcSEcCtD
Dexmedetomidine—Body temperature increased—Epirubicin—pancreatic cancer	0.00012	0.000467	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000116	0.00045	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000115	0.000447	CcSEcCtD
Dexmedetomidine—Abdominal pain—Doxorubicin—pancreatic cancer	0.000111	0.000432	CcSEcCtD
Dexmedetomidine—Body temperature increased—Doxorubicin—pancreatic cancer	0.000111	0.000432	CcSEcCtD
Dexmedetomidine—Diarrhoea—Epirubicin—pancreatic cancer	0.000104	0.000404	CcSEcCtD
Dexmedetomidine—Dizziness—Epirubicin—pancreatic cancer	0.000101	0.000391	CcSEcCtD
Dexmedetomidine—Vomiting—Epirubicin—pancreatic cancer	9.68e-05	0.000376	CcSEcCtD
Dexmedetomidine—Diarrhoea—Doxorubicin—pancreatic cancer	9.64e-05	0.000374	CcSEcCtD
Dexmedetomidine—Rash—Epirubicin—pancreatic cancer	9.6e-05	0.000373	CcSEcCtD
Dexmedetomidine—Dermatitis—Epirubicin—pancreatic cancer	9.59e-05	0.000372	CcSEcCtD
Dexmedetomidine—Headache—Epirubicin—pancreatic cancer	9.54e-05	0.00037	CcSEcCtD
Dexmedetomidine—Dizziness—Doxorubicin—pancreatic cancer	9.32e-05	0.000361	CcSEcCtD
Dexmedetomidine—Nausea—Epirubicin—pancreatic cancer	9.05e-05	0.000351	CcSEcCtD
Dexmedetomidine—Vomiting—Doxorubicin—pancreatic cancer	8.96e-05	0.000348	CcSEcCtD
Dexmedetomidine—Rash—Doxorubicin—pancreatic cancer	8.89e-05	0.000345	CcSEcCtD
Dexmedetomidine—Dermatitis—Doxorubicin—pancreatic cancer	8.88e-05	0.000344	CcSEcCtD
Dexmedetomidine—Headache—Doxorubicin—pancreatic cancer	8.83e-05	0.000342	CcSEcCtD
Dexmedetomidine—Nausea—Doxorubicin—pancreatic cancer	8.37e-05	0.000325	CcSEcCtD
Dexmedetomidine—ADRA1D—Signaling Pathways—EGF—pancreatic cancer	1.47e-05	0.000172	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TERT—pancreatic cancer	1.47e-05	0.000172	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—KDR—pancreatic cancer	1.46e-05	0.000171	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.46e-05	0.000171	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—PIK3CB—pancreatic cancer	1.46e-05	0.000171	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PPARG—pancreatic cancer	1.45e-05	0.00017	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—TYMS—pancreatic cancer	1.44e-05	0.000169	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HIF1A—pancreatic cancer	1.42e-05	0.000167	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TSC2—pancreatic cancer	1.42e-05	0.000167	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SMAD4—pancreatic cancer	1.41e-05	0.000166	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—AKT1—pancreatic cancer	1.41e-05	0.000166	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—PIK3CA—pancreatic cancer	1.4e-05	0.000165	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HIF1A—pancreatic cancer	1.4e-05	0.000164	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—CXCL8—pancreatic cancer	1.4e-05	0.000164	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TSC2—pancreatic cancer	1.4e-05	0.000164	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CD44—pancreatic cancer	1.4e-05	0.000164	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—APOE—pancreatic cancer	1.39e-05	0.000163	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NFKBIA—pancreatic cancer	1.39e-05	0.000163	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HES1—pancreatic cancer	1.38e-05	0.000162	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NOTCH1—pancreatic cancer	1.37e-05	0.000161	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—APOE—pancreatic cancer	1.37e-05	0.00016	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—KDR—pancreatic cancer	1.36e-05	0.00016	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—TP53—pancreatic cancer	1.36e-05	0.000159	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—EGFR—pancreatic cancer	1.36e-05	0.000159	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—APOE—pancreatic cancer	1.35e-05	0.000158	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CG—pancreatic cancer	1.34e-05	0.000157	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—NRAS—pancreatic cancer	1.34e-05	0.000157	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—KDR—pancreatic cancer	1.34e-05	0.000157	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GCG—pancreatic cancer	1.34e-05	0.000157	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.33e-05	0.000156	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EGF—pancreatic cancer	1.33e-05	0.000156	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PIK3CB—pancreatic cancer	1.32e-05	0.000155	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CD—pancreatic cancer	1.32e-05	0.000155	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CD—pancreatic cancer	1.31e-05	0.000153	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—HRAS—pancreatic cancer	1.3e-05	0.000152	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NFKBIA—pancreatic cancer	1.3e-05	0.000152	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.3e-05	0.000152	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NOTCH1—pancreatic cancer	1.28e-05	0.00015	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—KRAS—pancreatic cancer	1.28e-05	0.00015	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NFKBIA—pancreatic cancer	1.28e-05	0.000149	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—CXCL8—pancreatic cancer	1.27e-05	0.000149	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NOTCH1—pancreatic cancer	1.26e-05	0.000148	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—STK11—pancreatic cancer	1.26e-05	0.000147	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CG—pancreatic cancer	1.26e-05	0.000147	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—NRAS—pancreatic cancer	1.26e-05	0.000147	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EGF—pancreatic cancer	1.24e-05	0.000145	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—APOE—pancreatic cancer	1.24e-05	0.000145	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CG—pancreatic cancer	1.24e-05	0.000145	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—NRAS—pancreatic cancer	1.24e-05	0.000145	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—EGFR—pancreatic cancer	1.22e-05	0.000143	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EGF—pancreatic cancer	1.22e-05	0.000143	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CG—pancreatic cancer	1.22e-05	0.000143	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TERT—pancreatic cancer	1.21e-05	0.000142	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CD44—pancreatic cancer	1.18e-05	0.000139	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CD—pancreatic cancer	1.18e-05	0.000138	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—PIK3CA—pancreatic cancer	1.18e-05	0.000138	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PPARG—pancreatic cancer	1.18e-05	0.000138	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.17e-05	0.000137	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—APOE—pancreatic cancer	1.17e-05	0.000137	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.16e-05	0.000136	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HIF1A—pancreatic cancer	1.16e-05	0.000136	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—KRAS—pancreatic cancer	1.16e-05	0.000136	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TSC2—pancreatic cancer	1.15e-05	0.000135	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CB—pancreatic cancer	1.15e-05	0.000135	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—AKT1—pancreatic cancer	1.15e-05	0.000134	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.15e-05	0.000134	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—EGFR—pancreatic cancer	1.14e-05	0.000134	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CB—pancreatic cancer	1.14e-05	0.000134	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTGS2—pancreatic cancer	1.14e-05	0.000134	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GCG—pancreatic cancer	1.13e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—APOE—pancreatic cancer	1.13e-05	0.000132	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—EGFR—pancreatic cancer	1.13e-05	0.000132	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CG—pancreatic cancer	1.12e-05	0.000131	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.11e-05	0.00013	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KDR—pancreatic cancer	1.11e-05	0.00013	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CD—pancreatic cancer	1.1e-05	0.000129	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CXCL8—pancreatic cancer	1.1e-05	0.000128	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.09e-05	0.000128	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—HRAS—pancreatic cancer	1.09e-05	0.000128	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CD—pancreatic cancer	1.09e-05	0.000127	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—TYMS—pancreatic cancer	1.08e-05	0.000127	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PPARG—pancreatic cancer	1.08e-05	0.000127	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—KRAS—pancreatic cancer	1.08e-05	0.000127	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.08e-05	0.000126	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CD—pancreatic cancer	1.07e-05	0.000126	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—STK11—pancreatic cancer	1.07e-05	0.000125	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—KRAS—pancreatic cancer	1.06e-05	0.000125	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—PIK3CA—pancreatic cancer	1.06e-05	0.000125	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—AKT1—pancreatic cancer	1.06e-05	0.000124	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CG—pancreatic cancer	1.06e-05	0.000124	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NFKBIA—pancreatic cancer	1.05e-05	0.000123	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CASP3—pancreatic cancer	1.05e-05	0.000123	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NOTCH1—pancreatic cancer	1.04e-05	0.000122	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CB—pancreatic cancer	1.03e-05	0.000121	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCND1—pancreatic cancer	1.02e-05	0.00012	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CG—pancreatic cancer	1.02e-05	0.000119	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—NRAS—pancreatic cancer	1.02e-05	0.000119	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PPARG—pancreatic cancer	1.02e-05	0.000119	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CTNNB1—pancreatic cancer	1.01e-05	0.000119	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGF—pancreatic cancer	1.01e-05	0.000118	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1e-05	0.000117	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTEN—pancreatic cancer	9.94e-06	0.000116	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—PIK3CA—pancreatic cancer	9.92e-06	0.000116	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MMP9—pancreatic cancer	9.91e-06	0.000116	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CXCL8—pancreatic cancer	9.89e-06	0.000116	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PTEN—pancreatic cancer	9.85e-06	0.000116	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CD—pancreatic cancer	9.84e-06	0.000115	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—HRAS—pancreatic cancer	9.83e-06	0.000115	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—PIK3CA—pancreatic cancer	9.77e-06	0.000114	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CB—pancreatic cancer	9.62e-06	0.000113	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—AKT1—pancreatic cancer	9.61e-06	0.000113	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—AKT1—pancreatic cancer	9.56e-06	0.000112	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CASP3—pancreatic cancer	9.47e-06	0.000111	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CB—pancreatic cancer	9.46e-06	0.000111	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CB—pancreatic cancer	9.34e-06	0.000109	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—EGFR—pancreatic cancer	9.29e-06	0.000109	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CD—pancreatic cancer	9.28e-06	0.000109	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTGS2—pancreatic cancer	9.26e-06	0.000108	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CXCL8—pancreatic cancer	9.24e-06	0.000108	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCND1—pancreatic cancer	9.22e-06	0.000108	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—HRAS—pancreatic cancer	9.18e-06	0.000108	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—TYMS—pancreatic cancer	9.17e-06	0.000107	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SRC—pancreatic cancer	9.14e-06	0.000107	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CTNNB1—pancreatic cancer	9.13e-06	0.000107	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CXCL8—pancreatic cancer	9.1e-06	0.000107	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—HRAS—pancreatic cancer	9.04e-06	0.000106	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CD—pancreatic cancer	8.96e-06	0.000105	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MMP9—pancreatic cancer	8.95e-06	0.000105	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—AKT1—pancreatic cancer	8.93e-06	0.000105	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—VEGFA—pancreatic cancer	8.9e-06	0.000104	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PTEN—pancreatic cancer	8.9e-06	0.000104	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.88e-06	0.000104	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CASP3—pancreatic cancer	8.85e-06	0.000104	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—STAT3—pancreatic cancer	8.81e-06	0.000103	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—APOE—pancreatic cancer	8.8e-06	0.000103	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—NRAS—pancreatic cancer	8.79e-06	0.000103	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—AKT1—pancreatic cancer	8.79e-06	0.000103	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	8.77e-06	0.000103	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CASP3—pancreatic cancer	8.71e-06	0.000102	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—AKT1—pancreatic cancer	8.68e-06	0.000102	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCND1—pancreatic cancer	8.61e-06	0.000101	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CB—pancreatic cancer	8.58e-06	0.000101	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CTNNB1—pancreatic cancer	8.53e-06	9.99e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTGS2—pancreatic cancer	8.5e-06	9.96e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCND1—pancreatic cancer	8.47e-06	9.93e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CTNNB1—pancreatic cancer	8.39e-06	9.84e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MMP9—pancreatic cancer	8.36e-06	9.8e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PTEN—pancreatic cancer	8.31e-06	9.74e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SRC—pancreatic cancer	8.25e-06	9.67e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MMP9—pancreatic cancer	8.23e-06	9.64e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MYC—pancreatic cancer	8.19e-06	9.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PTEN—pancreatic cancer	8.18e-06	9.59e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TGFB1—pancreatic cancer	8.17e-06	9.58e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—AKT1—pancreatic cancer	8.11e-06	9.5e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CB—pancreatic cancer	8.09e-06	9.48e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTEN—pancreatic cancer	8.07e-06	9.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	8.06e-06	9.45e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—VEGFA—pancreatic cancer	8.04e-06	9.42e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTGS2—pancreatic cancer	8.01e-06	9.39e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EGFR—pancreatic cancer	8.01e-06	9.39e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—AKT1—pancreatic cancer	7.98e-06	9.35e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—STAT3—pancreatic cancer	7.96e-06	9.33e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	7.94e-06	9.31e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NRAS—pancreatic cancer	7.94e-06	9.3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	7.81e-06	9.16e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SRC—pancreatic cancer	7.71e-06	9.03e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PPARG—pancreatic cancer	7.67e-06	8.99e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SRC—pancreatic cancer	7.58e-06	8.89e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—KRAS—pancreatic cancer	7.57e-06	8.87e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	7.51e-06	8.8e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—VEGFA—pancreatic cancer	7.51e-06	8.8e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	7.46e-06	8.74e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—APOE—pancreatic cancer	7.46e-06	8.74e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—STAT3—pancreatic cancer	7.43e-06	8.71e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NRAS—pancreatic cancer	7.41e-06	8.69e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTEN—pancreatic cancer	7.41e-06	8.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MYC—pancreatic cancer	7.39e-06	8.67e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—VEGFA—pancreatic cancer	7.39e-06	8.66e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TGFB1—pancreatic cancer	7.38e-06	8.64e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—STAT3—pancreatic cancer	7.31e-06	8.57e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NRAS—pancreatic cancer	7.3e-06	8.55e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	7.25e-06	8.5e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EGFR—pancreatic cancer	7.23e-06	8.48e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	7.18e-06	8.42e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	7.06e-06	8.27e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CA—pancreatic cancer	7.01e-06	8.22e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	6.99e-06	8.2e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTEN—pancreatic cancer	6.99e-06	8.19e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	6.98e-06	8.19e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CA—pancreatic cancer	6.95e-06	8.15e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	6.93e-06	8.12e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MYC—pancreatic cancer	6.91e-06	8.09e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TGFB1—pancreatic cancer	6.89e-06	8.07e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—KRAS—pancreatic cancer	6.83e-06	8.01e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MYC—pancreatic cancer	6.8e-06	7.97e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	6.79e-06	7.96e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TGFB1—pancreatic cancer	6.78e-06	7.95e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EGFR—pancreatic cancer	6.75e-06	7.92e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	6.75e-06	7.91e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	6.73e-06	7.89e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TP53—pancreatic cancer	6.73e-06	7.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EGFR—pancreatic cancer	6.65e-06	7.79e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	6.58e-06	7.72e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PPARG—pancreatic cancer	6.5e-06	7.61e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HRAS—pancreatic cancer	6.43e-06	7.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—KRAS—pancreatic cancer	6.38e-06	7.48e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—KRAS—pancreatic cancer	6.28e-06	7.36e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CA—pancreatic cancer	6.28e-06	7.36e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	6.26e-06	7.34e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	6.1e-06	7.15e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	6.09e-06	7.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TP53—pancreatic cancer	6.07e-06	7.12e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	6.04e-06	7.08e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTGS2—pancreatic cancer	6.03e-06	7.07e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	6.02e-06	7.06e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	5.92e-06	6.93e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CA—pancreatic cancer	5.86e-06	6.87e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HRAS—pancreatic cancer	5.81e-06	6.81e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CA—pancreatic cancer	5.77e-06	6.76e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—AKT1—pancreatic cancer	5.73e-06	6.71e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	5.69e-06	6.67e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—AKT1—pancreatic cancer	5.68e-06	6.66e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TP53—pancreatic cancer	5.67e-06	6.65e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	5.61e-06	6.57e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	5.6e-06	6.56e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TP53—pancreatic cancer	5.58e-06	6.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	5.49e-06	6.43e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HRAS—pancreatic cancer	5.42e-06	6.36e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HRAS—pancreatic cancer	5.34e-06	6.26e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTEN—pancreatic cancer	5.26e-06	6.17e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CA—pancreatic cancer	5.23e-06	6.13e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	5.18e-06	6.08e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	5.16e-06	6.04e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—AKT1—pancreatic cancer	5.13e-06	6.01e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTGS2—pancreatic cancer	5.11e-06	5.99e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CA—pancreatic cancer	4.93e-06	5.78e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—AKT1—pancreatic cancer	4.79e-06	5.61e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	4.76e-06	5.58e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—AKT1—pancreatic cancer	4.71e-06	5.52e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—AKT1—pancreatic cancer	4.65e-06	5.45e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	4.61e-06	5.4e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTEN—pancreatic cancer	4.46e-06	5.22e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	4.41e-06	5.16e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—AKT1—pancreatic cancer	4.27e-06	5.01e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—AKT1—pancreatic cancer	4.03e-06	4.72e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	3.89e-06	4.56e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	3.71e-06	4.35e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	3.14e-06	3.68e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—AKT1—pancreatic cancer	3.03e-06	3.55e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—AKT1—pancreatic cancer	2.57e-06	3.01e-05	CbGpPWpGaD
